Anti-IL-21 antibody [EPR4907]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Rabbit Recombinant Monoclonal IL-21 antibody. Suitable for WB and reacts with Recombinant full length protein - Human samples. Cited in 1 publication.
View Alternative Names
Interleukin-21, IL-21, Za11, IL21
- WB
Supplier Data
Western blot - Anti-IL-21 antibody [EPR4907] (AB178694)
All lanes:
Western blot - Anti-IL-21 antibody [EPR4907] (ab178694) at 1/10000 dilution
All lanes:
Human IL21 recombinant protein at 0.005 µg
Predicted band size: 17 kDa
false
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
Journal of oncology 2022:5054324 PubMed35578598
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com